FINWIRES · TerminalLIVE
FINWIRES

TransThera Sciences Gets China Approval for Cancer Study; to Partner with Shanghai Allist Pharma on Phase 2 Trial

By

TransThera Sciences (Nanjing) (HKG:2617) said Chinese regulators approved its phase 2 clinical trial of tinengotinib to treat prostate cancer, according to a Tuesday filing with the Hong Kong bourse.

The company's shares fell over 3% in afternoon trade Wednesday.

The firm will evaluate a combination of tinengotinib and novel hormone therapy in an open-label study in subjects with metastatic castration-resistant prostate cancer.

In a separate announcement, the firm said it is partnering with Shanghai Allist Pharmaceuticals on another open-label phase 2 study to evaluate TT-00973-MS tablets in combination with firmonertinib mesylate tablets in patients with locally advanced or metastatic non-small cell lung cancer.

Based on the results of the study, the parties may collaborate on a phase 3 study.

Related Articles

Asia

Hengrui Pharma Gets China Greenlight for Multiple Myeloma Drug Trial

Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Suzhou Shengdiya Biopharmaceutical received China's regulatory approval to start clinical trials for SHR-5421.The approval is for the anti-tumor drug's clinical research in multiple myeloma, according to a Tuesday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 2% in recent trade.

$SHA:600276
Asia

Yuneng Gets Warnings Over Disclosure Breaches; Shares Dip 7%

Henan Yuneng (SHE:001896) received a warning from the China Securities Regulatory Commission's Henan Bureau for breaches in disclosure, according to a Shenzhen bourse filing on Wednesday.The regulator's investigation found that the power company failed to publish complete information and risk warnings for an equity investment transaction in February, and failed to establish and implement an insider information registration management system.The company's shares dropped nearly 7% during the afternoon trade.

$SHE:001896
Asia

Taiwan Consumer Confidence Falls Slightly in May as Stock Investment Sentiment Weakens

Taiwan's consumer confidence index (CCI) slipped to 62.08 in May, down 0.39 points from April, the Economic Development Research Center at National Central University said Wednesday.The decline was driven by weaker sentiment across five sub-indicators, with confidence in stock investment opportunities posting the largest monthly drop.The sub-indicators that dropped are investing in stocks, which recorded the largest decline, purchasing durable goods, domestic economic outlook, household financial situation and employment opportunities. Meanwhile, expectations for price levels over the next six months recorded the only increase among the six indicators.All six core sub-indicators point toward pessimism among consumers, the report said.

$^TWII